TARS3: A Potential Drug Target and Biomarker (G123283)
TARS3: A Potential Drug Target and Biomarker
TARS3 (thrRS) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. TARS3 is a non-coding RNA molecule that has been shown to play a role in the regulation of gene expression and has been linked to the development and progression of various diseases.
One of the most promising aspects of TARS3 is its potential as a drug target. The TARS3 gene has been shown to be involved in the regulation of cell proliferation and has been linked to the development of cancer. By targeting the TARS3 gene, researchers may be able to develop new treatments for cancer and other diseases.
In addition to its potential as a drug target, TARS3 has also been shown to be a potential biomarker for various diseases. The TARS3 gene has been shown to be expressed in a variety of tissues and has been linked to the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. By analyzing the expression of the TARS3 gene in different tissues, researchers may be able to develop new diagnostic tests for these diseases and potentially identify new targets for treatment.
Another promising aspect of TARS3 is its role in the regulation of stem cell proliferation. The TARS3 gene has been shown to play a role in the regulation of stem cell proliferation and has been linked to the development of various diseases, including cancer. By targeting the TARS3 gene, researchers may be able to develop new treatments for cancer and other diseases that involve stem cell proliferation.
In conclusion, TARS3 is a gene that has the potential to be a drug target and biomarker for a variety of diseases. Further research is needed to fully understand the role of TARS3 in the regulation of gene expression and the development and progression of various diseases. By targeting the TARS3 gene, researchers may be able to develop new treatments and diagnostic tests for a variety of diseases.
Protein Name: Threonyl-tRNA Synthetase 3
Functions: Catalyzes the attachment of threonine to tRNA(Thr) in a two-step reaction: threonine is first activated by ATP to form Thr-AMP and then transferred to the acceptor end of tRNA(Thr). Also edits incorrectly charged tRNA(Thr) via its editing domain, at the post-transfer stage
More Common Targets
TAS1R1 | TAS1R2 | TAS1R3 | TAS2R1 | TAS2R10 | TAS2R13 | TAS2R14 | TAS2R16 | TAS2R19 | TAS2R20 | TAS2R3 | TAS2R30 | TAS2R31 | TAS2R38 | TAS2R39 | TAS2R4 | TAS2R40 | TAS2R41 | TAS2R42 | TAS2R43 | TAS2R45 | TAS2R46 | TAS2R5 | TAS2R50 | TAS2R60 | TAS2R63P | TAS2R64P | TAS2R7 | TAS2R8 | TAS2R9 | TASL | TASOR | TASOR2 | TASP1 | Taste receptor type 2 | Taste Receptors Type 1 | TAT | TAT-AS1 | TATDN1 | TATDN2 | TATDN2P3 | TATDN3 | TAX1BP1 | TAX1BP3 | TBATA | TBC1D1 | TBC1D10A | TBC1D10B | TBC1D10C | TBC1D12 | TBC1D13 | TBC1D14 | TBC1D15 | TBC1D16 | TBC1D17 | TBC1D19 | TBC1D2 | TBC1D20 | TBC1D21 | TBC1D22A | TBC1D22A-AS1 | TBC1D22B | TBC1D23 | TBC1D24 | TBC1D25 | TBC1D26 | TBC1D27P | TBC1D28 | TBC1D29P | TBC1D2B | TBC1D3 | TBC1D30 | TBC1D31 | TBC1D32 | TBC1D3B | TBC1D3C | TBC1D3F | TBC1D3G | TBC1D3H | TBC1D3L | TBC1D3P1 | TBC1D3P2 | TBC1D4 | TBC1D5 | TBC1D7 | TBC1D8 | TBC1D8-AS1 | TBC1D8B | TBC1D9 | TBC1D9B | TBCA | TBCB | TBCC | TBCCD1 | TBCD | TBCE | TBCEL | TBCK | TBILA | TBK1